Mike Mensinger - 27 Oct 2026 Form 4 Insider Report for Beta Bionics, Inc. (BBNX)

SEC form
4
Accepted by SEC
29 Oct 2026, 16:22:20 UTC
Prior SEC filing
17 Sep 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Mike Mensinger filed Form 4 for Beta Bionics, Inc. (BBNX) on 29 Oct 2026.

Key facts

  • This page summarizes Mike Mensinger's Form 4 filing for Beta Bionics, Inc. (BBNX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 29 Oct 2026, 16:22.

Change

  • Previous filing in this sequence was filed on 17 Sep 2026.
  • Current net transaction value: -$58,300.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002048500 Primary reporting owner

Mensinger Mike

Relationship
Chief Product Officer

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBNX transaction

Common Stock

Sale

Transaction value
-$58,300
Shares
-2,650
Change %
-1.5%
Price
$22.00
Shares after
174,740
Date
27 Oct 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .